- AU$894.68m
- AU$820.00m
- $90.18m
Saluda Medical's shares hit record low on Evoke device recall
Australia's Saluda Medical hits record low on voluntary device field action
Brief: Saluda Medical Expands Access To FDA-Approved Closed-Loop Surgical Paddle Lead
Brief: Saluda Medical Appoints Mike Mathias As CEO Replacing Barry Regan
Brief: Saluda Medical Sees FY27 Revenue Growth Between 25% And 35% Versus FY26
Brief: Saluda Medical Posts Fy26 Revenue From Ordinary Activities $90.2 Million
Brief: Saluda Medical Reports FY26 Full-Year Revenue $90.2 Million
Brief: Saluda Medical Receives U.S. FDA Approval For New Cap24™ Surgical Paddle Lead
Australia's Saluda Medical rises as FDA approves pain-treatment device for US market
Brief: Saluda Medical Receives FDA Approval For Cap24 Surgical Paddle Lead
Australia's Saluda Medical climbs on strong revenue growth, forecast hike
Brief: Saluda Medical Says FY26 Revenue Guidance Increased To $85 Million
Brief: Saluda Medical Inc Gets Regulatory Approval For Eva Sensing Technology In Europe With Recognition In Australia
Brief: Saluda Medical Lists On ASX After A$230.8 Mln IPO
Saluda Medical slumps nearly 50% in bruising ASX debut
Saluda Medical shares plummet on Australian market debut (updated)
Saluda Medical shares slump on Australian market debut